In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

Second Time Lucky

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

PolyPid seeking US partner for lead candidate D-PLEX100 for post-surgery infections.  • Source: Shutterstock

Following a missed Phase III endpoint in 2022, PolyPid has reported positive top-line results from its Phase III SHIELD II trial with D-PLEX100 for the prevention of surgical site infections (SSIs) in patients undergoing major abdominal colorectal surgery.

The doxycycline-containing, sustained release polymer matrix product, the Israeli firm’s lead candidate, has US Fast Track designation and is on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

15 Jul 2025

• By Alaric DeArment

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

Takeda Prepares Ground For Oveporexton In Narcolepsy

14 Jul 2025

• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

14 Jul 2025

• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

14 Jul 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Takeda Prepares Ground For Oveporexton In Narcolepsy

14 Jul 2025

• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.